CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Neomycin and Polymyxin B Sulfates and Dexamethasone

· ingredient dexamethasoneAntibiotics· DEXAMETHASONE 1 mg/g; NEOMYCIN SULFATE 3.5 mg/g
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$2.76
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per GM — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other dexamethasone products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.

ProductNADAC / GMvs this
Dexamethasone$0.10682−$2.65
Dexamethasone$0.15403−$2.60
Dexamethasone$0.19895−$2.56
TaperDex 12-day$0.19895−$2.56
dexamethasone$0.20711−$2.55
dexamethasone$0.25646−$2.50
Dexamethasone Sodium Phosphate$0.69334−$2.06
Dexamethasone Sodium Phosphate$0.69334−$2.06

Medicare Part D coverage · CY2026

On 328 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 1% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.